Monoclonal antibody therapy in the treatment of non-hodgkin lymphoma

JAMA

Volumn 286, Issue 10, 2001, Pages 1149-1152

  McCune, S L ^a   Gockerman, J P ^a   Rizzieri, D A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HUMAN MONOCLONAL ANTIBODY; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; IODINE 131; MONOCLONAL ANTIBODY; OKT 3; PALIVIZUMAB; PREDNISONE; RITUXIMAB; STEROID; TENASCIN; TOSITUMOMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90;

ANTIGEN ANTIBODY REACTION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CROHN DISEASE; DRUG INDUCED DISEASE; DRUG MECHANISM; FEVER; HUMAN; HUMAN CELL; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY GRAFT REJECTION; LEUKEMIA; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SHORT SURVEY; TREATMENT INDICATION;

EID: 0035850404     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.10.1149     Document Type: Short Survey

References (31)

1. Cancer statistics, 2001
2. The humanized anti-CD20 antibody Rituxan induces apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells in vitro and in vivo, through a p38 MAP-kinase dependent signaling pathway
3. Effector cell-mediated mechanisms play the dominant role in the cytotoxicity of Rituximab on human peripheral blood B cells from normal donors and patients with chronic lymphocytic leukemia
4. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
5. Thrice weekly rituximab demonstrates significant activity in chronic lymphocytic leukemia
6. Rituximab (Mabthera) as single agent and in combination with interferon-α-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas
7. Campath-1H is an effective salvage therapy for fludarabine failing CLL patients
8. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic
9. Augmentation of the anti-lymphoma activity of an anti-CD19 immunotoxin by anti-CD20 antibody is mediated via a complement-mediated mechanism
10. Therapeutic index of IDEC-Y2B8 radioimmunotherapy
11. Reduced dose Zevalin is safe and effective in patients with relapsed or refractory, low grade, follicular or CD20+ transformed B cell NHL and mild thrombocytopenia
12. Interim efficacy results of Bexxar in a large multicenter expanded access study
13. Iodine I131 tositumomab for patients with low grade or transformed low grade NHL
14. Multicenter phase II study of iodine 131 tositumomab for chemotherapy - Relapsed refractory low grade and transformed low grade B cell NHL
15. Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma
16. Expression of tenascin is related to histologic malignancy and angiogenesis in B-cell non-Hodgkin's lymphomas
17. Markers of angiogenesis, factor VIII and tenascin, correlate with disease activity in patients with non-Hodgkin's lymphoma
18. The mechanism of in vivo leukemia cell clearance by rituximab in patients with CLL involves apoptosis by a caspase 9 pathway
19. Phase II study of rituximab in combination with fludarabine in patients with low grade or follicular B-cell lymphoma
20. Molecular responses with FND + Rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin's lymphoma
21. Relapsed follicular lymphoma response to fludarabine - Mitoxantrone regimen and monoclonal anti-CD20
22. CAMPATH-1H with fludarabine
23. Clinical outcomes of patients treated with rituximab for relapsed or refractory aggressive non-Hodgkin's lymphoma in the post transplant setting
24. Rituxan and vinorelbine combination is active in the treatment of NHL relapsing post-transplant
25. Mabthera (Rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL)
26. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab
27. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group
28. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma
29. Mechanisms of action of CAMPATH-1 antibodies
30. Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice
31. Tumor localization by combinations of monoclonal antibodies in a new human carcinoma cell line (LIM1899)